Last C$1.35 CAD
Change Today +0.10 / 8.00%
Volume 95.1K
As of 3:57 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

genenews ltd (GEN) Snapshot

Open
C$1.30
Previous Close
C$1.25
Day High
C$1.35
Day Low
C$1.27
52 Week High
03/26/14 - C$1.70
52 Week Low
11/8/13 - C$0.34
Market Cap
68.9M
Average Volume 10 Days
21.1K
EPS TTM
C$-0.22
Shares Outstanding
51.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENENEWS LTD (GEN)

Related News

No related news articles were found.

genenews ltd (GEN) Related Businessweek News

No Related Businessweek News Found

genenews ltd (GEN) Details

GeneNews Limited, a molecular diagnostics company, focuses on the development and application of functional genomics to enable early diagnosis and personalized health management based on disease specific biomarkers. Its principal platform technology, the Sentinel Principle, detects and stages various diseases or medical conditions from a blood sample. The company is applying the Sentinel Principle in the areas of cancer, arthritis, cardiovascular diseases, and neurological disorders. Its lead product includes ColonSentry, a blood-based molecular test to aid physicians in determining an individual’s risk of having colorectal cancer. The company was formerly known as ChondroGene Limited and changed its name to GeneNews Limited in October 2006. GeneNews Limited was founded in 1998 and is headquartered in Markham, Canada.

Founded in 1998

genenews ltd (GEN) Top Compensated Officers

Executive Chairman, Member of Compensation & ...
Total Annual Compensation: --
Chief Financial Officer, Treasurer, Director ...
Total Annual Compensation: C$131.3K
Executive Vice President of US Corporate Deve...
Total Annual Compensation: C$198.6K
Compensation as of Fiscal Year 2013.

genenews ltd (GEN) Key Developments

GeneNews Limited Reports Earnings Results for the Second Quarter Ended June 30, 2014

GeneNews Limited reported earnings results for the second quarter ended June 30, 2014. For the three months ended June 30, 2014, the company’s total revenues were approximately CAD 0.40 million as compared to CAD 0.01 million in the same period in 2013. The net loss for the second quarter of 2014 was approximately CAD 2.7 million, or CAD 0.06 loss per common share, as compared to a net loss of approximately CAD 1.9 million, or CAD 0.06 loss per common share for the same three-month period in 2013. The increase in loss in the 2014 second quarter was primarily due to the Company's share of the loss of Innovative Diagnostic Laboratory, LLP (IDL) of CAD 1.8 million, partially offset by a CAD 0.6 million reduction in its restructured research and development costs and the increase in revenues of CAD 0.4 million.

GeneNews Limited Reports Consolidated Financial Results for the Three Months Period Ended March 31, 2014

GeneNews Limited reported consolidated financial results for the three months period ended March 31, 2014. For the three months ended March 31, 2014, the company's total revenues were approximately $0.2 million as compared to $0.05 million in the same period in 2013. The net loss for the first quarter of 2014 was approximately $1.8 million or $0.04 loss per common share, as compared to a net loss of approximately $1.5 million, or $0.07 loss per common share for the same three-month period in 2013. The increase in loss in the 2014 first quarter was primarily due to the company's share of the loss in its investment IDL of $1.0 million, partially offset by a reduction in the restructured research and development costs of $0.5 million and the increase in revenues of $0.2 million.

GeneNews Limited, Annual General Meeting, May 14, 2014

GeneNews Limited, Annual General Meeting, May 14, 2014., at 16:30 Eastern Daylight. Location: Fasken Martineau DuMoulin LLP. Agenda: To receive the audited consolidated financial statements of the corporation for the year ended December 31, 2013, and the report of the auditor thereon; to consider and, if thought fit, to pass a resolution electing as directors of the Corporation for the ensuing year the nominees proposed by management of the Corporation; to consider and, if thought fit, to pass a resolution approving the reappointment of Ernst & Young LLP, Chartered Accountants as auditor for the fiscal year ending December 31, 2013, and to authorize the directors of the Corporation to fix their remuneration; and to transact such other business as may properly come before the Meeting and any adjournment or postponement thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEN:CN C$1.35 CAD +0.10

GEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GEN.
View Industry Companies
 

Industry Analysis

GEN

Industry Average

Valuation GEN Industry Range
No financial data is available for GEN.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENENEWS LTD, please visit www.genenews.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.